00000000nam 2200000zi 4500
0019.950905
003CaOODSP
00520250521125201
006m     o  d f      
007cr mn|||||||||
008250507e202505  onc     ob   f000 0 eng d
020 |a9780660772011 |q(statement)
020 |a9780660772028 |q(summary)
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aHP40-389/2025E-PDF
0861 |aHP40-389/2025-1E-PDF
24500|aNACI rapid response : |bupdated guidance on the use of Imvamune® for the prevention of mpox.
264 1|aOttawa, ON : |bPublic Health Agency of Canada = Agence de la santé publique du Canada, |cMay 2025.
264 4|c©2025
300 |a1 online resource (27 pages) + |esummary (5 pages)
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aIssued also in French under title: Réponse rapide du CCNI : mise à jour des directives sur l'utilisation d'ImvamuneMD pour la prévention de la mpox.
500 |aFrom the cover: An Advisory COmmittee Statement (ACS). National Advisory Committee on Immunization (NACI)."
500 |a"Pub.: 250051."
500 |a"Pub.: 250053."
504 |aIncludes bibliographical references (pages 23-27).
650 0|aHuman monkeypox|xVaccination|zCanada.
650 0|aHuman monkeypox|xVaccination|xGovernment policy|zCanada.
7102 |aPublic Health Agency of Canada, |eissuing body.
7101 |aCanada. |bNational Advisory Committee on Immunization, |eissuing body.
77508|tRéponse rapide du CCNI : |w(CaOODSP)9.950906
85640|qPDF|s482 KB|uhttps://publications.gc.ca/collections/collection_2025/aspc-phac/HP40-389-2025-eng.pdf|z(statement)
85640|qPDF|s253 KB|uhttps://publications.gc.ca/collections/collection_2025/aspc-phac/HP40-389-2025-1-eng.pdf|z(summary)
8564 |qHTML|sN/A|uhttps://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-summary-rapid-response-updated-guidance-use-imvamune-prevention-mpox.html|z(summary)